李輝讀書報(bào)告(存儲(chǔ)版)
【正文】 se. NAFLD and NASH ? Nonalcoholic fatty liver disease(NAFLD) is characterized by hepatic steatosis in the absence of a history of significant alcohol use or other known liver disease. ? Nonalcoholic Steatohepatitis(NASH) is a progressive form of NAFLD and includes inflammatory ponents on pathology. The NASH Clinical Research Network designed and validated a pathologic scoring system for NASH that is the sum of measures of steatosis, lobular inflammation, and hepatocellular ballooning. NAFLD and NASH ? The gold standard for the diagnosis of both NAFLD and NASH is tissue biopsy. ? NAFLD prises a spectrum of disorders from fatty liver disease to progressive inflammation and cirrhosis. ? Approximately 10% of patients with NAFLD progress NASH, and 8% to 26% of individuals with NASH progress to cirrhosis. ? Retrospective data suggest that, after cirrhosis develops,4% to 27% of cases of NASH transform to HCC. Metabolic syndrome ? It is likely that the majority of those with metabolic syndrome who develop HCC also have cirrhosis before their diagnosis, although this also is unproven. ? Case reports have described patients with NASH who developed cirrhosis and then HCC, and animal models have demonstrated a clear progression from NASH, to cirrhosis, to cancer. Obesity and Cancer Risk Several studies suggest that obese patients also are at increased risk for several types of cancer, both in the United States and in other countries. A large metaanalysis published in The Lancet indicated that increased BMI wa
醫(yī)療健康相關(guān)推薦
鄂ICP備17016276號(hào)-1